PharmacyCodes



Bentiromidum [INN-Latin] en es it fr

Bentiromidum [INN-Latin] Brand names, Bentiromidum [INN-Latin] Analogs

Bentiromidum [INN-Latin] Brand Names Mixture

  • No information avaliable

Bentiromidum [INN-Latin] Chemical_Formula

C23H20N2O5

Bentiromidum [INN-Latin] RX_link

No information avaliable

Bentiromidum [INN-Latin] fda sheet

Bentiromidum [INN-Latin] msds (material safety sheet)

Bentiromidum [INN-Latin] Synthesis Reference

No information avaliable

Bentiromidum [INN-Latin] Molecular Weight

404.415 g/mol

Bentiromidum [INN-Latin] Melting Point

241 oC

Bentiromidum [INN-Latin] H2O Solubility

No information avaliable

Bentiromidum [INN-Latin] State

Solid

Bentiromidum [INN-Latin] LogP

3.201

Bentiromidum [INN-Latin] Dosage Forms

No information avaliable

Bentiromidum [INN-Latin] Indication

Used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy.

Bentiromidum [INN-Latin] Pharmacology

Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. It is given by mouth as a noninvasive test. The amount of p-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the U.S. or Canada.

Bentiromidum [INN-Latin] Absorption

No information avaliable

Bentiromidum [INN-Latin] side effects and Toxicity

Symptoms of overdose include shortness of breath and troubled breathing.

Bentiromidum [INN-Latin] Patient Information

Bentiromidum [INN-Latin] Organisms Affected

Humans and other mammals